Skip to main content

Table 4 Initial source for disease progression: By anatomic site

From: Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression

Anatomic site of disease progression

Number of patients

(n (%))

 
 

Visceral involvement

No visceral involvement

p-value

Bone (BSLA only)

16 (42.1)

43 (58.9)

0.006

Visceral disease

12 (31.6)

9 (12.3)

Lymph node

1 (2.6)

12 (16.4)

Multiple sites*

9 (23.7)

9 (12.3)

  1. * Multiple sites: initial disease progression by RECIST which involves more than one type of anatomic site or simultaneous progression by RECIST and BSLA